In vivo validation using a xenograft mouse model demonstrated that overexpression of wild‐type TWF2 resulted in increased tumor burden following sunitinib treatment, whereas the M99A mutant failed to induce resistance (Figure 7H). Here, TWF2 is linked to neoplasm.